Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries

Basit Öğe Kaydı
dc.authoridLewandowska, Katarzyna/0000-0002-4648-2864
dc.authorscopusid57202210507
dc.authorscopusid57203066779
dc.authorscopusid6603063177
dc.authorscopusid57197907129
dc.authorscopusid7102893051
dc.authorscopusid6701659308
dc.authorscopusid35459711900
dc.contributor.authorKolonics-Farkas, Abigel Margit
dc.contributor.authorSterclova, Martina
dc.contributor.authorMogulkoc, Nesrin
dc.contributor.authorLewandowska, Katarzyna
dc.contributor.authorMuller, Veronika
dc.contributor.authorHajkova, Marta
dc.contributor.authorKramer, Mordechai
dc.date.accessioned2023-01-12T20:15:24Z
dc.date.available2023-01-12T20:15:24Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractIdiopathic pulmonary fibrosis (IPF) is a rare lung disease with poor prognosis. The diagnosis and treatment possibilities are dependent on the health systems of countries. Hence, comparison among countries is difficult due to data heterogeneity. Our aim was to analyse patients with IPF in Central and Eastern Europe using the uniform data from the European Multipartner IPF registry (EMPIRE), which at the time of analysis involved 10 countries. Newly diagnosed IPF patients (N = 2,492, between March 6, 2012 and May 12, 2020) from Czech Republic (N = 971, 39.0%), Turkey (N = 505, 20.3%), Poland (N = 285, 11.4%), Hungary (N = 216, 8.7%), Slovakia (N = 149, 6.0%), Israel (N = 120, 4.8%), Serbia (N = 95, 3.8%), Croatia (N = 87, 3.5%), Austria (N = 55, 2.2%), and Bulgaria (N = 9, 0.4%) were included, and Macedonia, while a member of the registry, was excluded from this analysis due to low number of cases (N = 5) at this timepoint. Baseline characteristics, smoking habit, comorbidities, lung function values, CO diffusion capacity, high-resolution CT (HRCT) pattern, and treatment data were analysed. Patients were significantly older in Austria than in the Czech Republic, Turkey, Hungary, Slovakia, Israel, and Serbia. Ever smokers were most common in Croatia (84.1%) and least frequent in Serbia (39.2%) and Slovakia (42.6%). The baseline forced vital capacity (FVC) was >80% in 44.6% of the patients, between 50 and 80% in 49.3%, and 80% were registered in Poland (63%), while the least in Israel (25%). A typical usual interstitial pneumonia (UIP) pattern was present in 67.6% of all patients, ranging from 43.5% (Austria) to 77.2% (Poland). The majority of patients received antifibrotic therapy (64.5%); 37.4% used pirfenidone (range 7.4-39.8% between countries); and 34.9% nintedanib (range 12.6-56.0% between countries) treatment. In 6.8% of the cases, a therapy switch was initiated between the 2 antifibrotic agents. Significant differences in IPF patient characteristics and access to antifibrotic therapies exist in EMPIRE countries, which needs further investigation and strategies to improve and harmonize patient care and therapy availability in this region.en_US
dc.description.sponsorshipBoehringer Ingelheim (BI); F. Hoffman-La Roche (Roche)en_US
dc.description.sponsorshipThe EMPIRE registry and this investigator-initiated study have been supported with funding from Boehringer Ingelheim (BI) and F. Hoffman-La Roche (Roche). BI and Roche had no role in the study design, analysis, or interpretation of the results. BI and Roche were given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BI and Roche substances and intellectual property considerations.en_US
dc.identifier.doi10.3389/fmed.2021.729203
dc.identifier.issn2296-858X
dc.identifier.pmid35004713en_US
dc.identifier.scopus2-s2.0-85122331056en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fmed.2021.729203
dc.identifier.urihttps://hdl.handle.net/11454/78460
dc.identifier.volume8en_US
dc.identifier.wosWOS:000745232800001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers in Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectIPFen_US
dc.subjecttreatmenten_US
dc.subjectregional accessibilityen_US
dc.subjectregistry analysisen_US
dc.subjectCentral-Eastern Europeen_US
dc.subjectIdiopathic Pulmonary-Fibrosisen_US
dc.subjectControlled-Trialsen_US
dc.subjectRegistryen_US
dc.subjectCohorten_US
dc.titleDifferences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countriesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu